Test Price
200 AEDโ Home Collection Available
Immunohistochemistry HER-2/ERBB2 (Breast) Test in UAE | 200 AED | DHA Licensed
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing.
- Premium Logistics: Secure Medical Courier Solid Tissue Specimen Retrieval via ISO-certified cold-chain transport from accredited hospitals.
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The Immunohistochemistry HER-2/ERBB2 test quantifies human epidermal growth factor receptor 2 protein overexpression in breast cancer tissue, guiding targeted therapy eligibility. Quantitative IHC is performed using an automated DAKO system, validated per ASCO/CAP guidelines, ensuring reproducible and clinically actionable results.
| Feature | Our Test (UAE Premium) | Alternative IHC Labs |
|---|---|---|
| Methodology | Quantitative IHC with automated DAKO system, validated per ASCO/CAP guidelines | Manual IHC, variable scoring |
| Turnaround Time | 5โ7 business days (urgent 3-day available) | 7โ10 business days |
| Price (AED) | 200 AED | 250โ350 AED |
| ISO Accreditation | ISO 9001:2015 (Cert: INT/EGQ/2509DA/3139) | Variable |
Physician Insight & Safety Protocols
"As a Specialist Diagnostic Radiologist, I emphasize that HER-2 status must be interpreted in conjunction with full histopathology and clinical context; a positive result does not automatically mandate trastuzumab without multidisciplinary review. Always discuss treatment modifications with your oncologistโnever self-discontinue medications."
โ Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology, DHA Registration ID: 61713011
Therapy Advisory Notice
Medication Caution
Do not discontinue or alter prescribed therapy without consulting your treating oncologist. Any changes to medication based on test results require a formal multidisciplinary review and should never be self-initiated.
Patient Exclusion Criteria & Emergency Red Flags
- Active bleeding or infection at biopsy site โ postpone collection until resolved.
- Severe systemic illness contraindicating tissue biopsy procedure.
- If you experience sudden severe pain, fever above 38.5ยฐC, or uncontrolled bleeding after tissue extraction, go immediately to the nearest emergency department.
Patient FAQ & Clinical Guidance
1. What does the HER-2 IHC test detect and why is it critical for breast cancer treatment?
This test measures the amount of HER-2 protein on the surface of cancer cells, which directly determines eligibility for targeted therapies such as trastuzumab, improving survival rates in HER-2-positive breast cancer. Results are always interpreted alongside full histopathology and clinical history.
2. What type of tissue sample is required for this test?
The test requires a formalin-fixed paraffin-embedded (FFPE) tissue block or biopsy slides from a previous surgical excision or core needle biopsy. A copy of the histopathology report, biopsy site details, and relevant clinical history must accompany the specimen to ensure accurate interpretation.
3. How is the tissue specimen collected and transported?
This test uses archival tissue specimens only. Existing FFPE blocks or slides are retrieved via Secure Medical Courier Solid Tissue Specimen Retrieval from the originating hospital or pathology lab. New tissue acquisition requires a hospital-based biopsy procedure; mobile home phlebotomy is not applicable for this solid tissue assay.
UAE Regulatory & Data Privacy Adherence
This test and all associated sample handling comply with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. All patient data is encrypted, access-controlled, and processed exclusively within UAE jurisdictional boundaries.
Clinical & Logistical Metadata
| Test Name | Immunohistochemistry HER-2/ERBB2 (Breast) |
| Price (AED) | 200 AED |
| Turnaround Time | 5โ7 business days (urgent 3-day available) |
| Sample Type / Matrix | Formalin-Fixed Paraffin-Embedded (FFPE) Tissue Block or Biopsy Slides |
| Methodology Used | Quantitative IHC with automated DAKO system, validated per ASCO/CAP guidelines |
| ICD-10-CM Code | C50.9 (Malignant neoplasm of breast, unspecified) |
| LOINC Code | 48658-2 (HER2 IHC [Interpretation] in Tissue) |
| DHA Facility License & Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians